Pharma and Biotech Consulting for Physicians (2026): What MSL, Advisory Board, and Expert Network Income Actually Look Like

Why "MSL" Is the Wrong Search Term for Most Physicians

Medical Science Liaisons serve as the field-based scientific bridge between a pharmaceutical or biotech company and the key opinion leaders (KOLs), academic centers, and specialists who influence how a drug or therapy is understood and adopted. It is a genuinely well-compensated, full-time career: average total compensation across recent data sources ranges from approximately $150,000 to $220,000, with senior and specialized MSLs (oncology, rare disease, gene therapy) reaching $240,000 to $380,000 at the top of the market, plus bonuses, equity in some biotech settings, and profit sharing.

The reason this role rarely fits a practicing physician's situation: MSL positions are field-based, full-time, and travel-intensive — most MSLs travel 60 to 80 percent of the time, visiting KOLs at academic medical centers, attending regional advisory boards, and working conferences, with weeks where they are away from home 5 or 6 nights. It is structurally a full-time career transition out of clinical practice, not a nights-and-weekends supplement to it. The typical entry pathway is a PharmD or PhD in a life science field, with MD/DO-credentialed MSLs being a distinct minority of the field workforce — physicians who do pursue this path are almost always doing so as a deliberate, complete exit from clinical medicine rather than an addition to it.

If your actual goal is supplemental income while continuing to practice, the roles below are the ones that fit that goal. If your goal is a full career transition, the "Full-Time Exit" section further down covers the physician-specific version of industry medical affairs work — typically titled Medical Director, not MSL.

The Roles That Actually Work as Physician Side Income

1. Advisory Board Participation

This is the most common, most accessible, and typically highest single-engagement payment available to a practicing physician with genuine subspecialty expertise. A pharmaceutical or device company convening an advisory board brings together a small group of physicians — often 6 to 15 — with relevant clinical expertise to advise on a specific drug, device, clinical trial design, or unmet clinical need in their specialty.

How it works: You are contacted, typically by a medical affairs or market research team (sometimes directly, often through a market research firm acting on the company's behalf), invited to participate in either an in-person or virtual advisory board session, and paid an honorarium for your time and preparation, structured through a written consulting agreement. Sessions typically run 2 to 4 hours; preparation (reviewing materials in advance) is usually compensated as part of the total fee.

What determines whether you get invited: Companies select advisory board participants based on documented clinical expertise, publication history, involvement in relevant clinical trials, leadership roles in professional societies, and prescribing or procedural volume in the relevant therapeutic area. Building a visible academic and professional profile — publications, society leadership, conference speaking — is the actual "application process" for this work, since there is no formal job posting to apply to.

Compensation: Total payment for a single advisory board session commonly runs from the low thousands to $5,000 or more depending on specialty, seniority, and the value the company places on the physician's specific expertise — structured as an honorarium under a written consulting agreement.

2. Speaker Programs

A speaker program is a paid engagement where a physician presents on a disease state or a specific drug's clinical data to other healthcare providers, typically at a dinner meeting, lunch program, or virtual session organized by a pharmaceutical company's speaker bureau. Physicians selected for speaker bureaus generally complete company-provided training on the specific content and undergo compliance and regulatory review before their first program.

The honest reality of speaker programs in 2026: Compliance scrutiny on speaker programs has intensified considerably over the past decade, and several major pharmaceutical companies have scaled back speaker bureau spending in response to Department of Justice settlements involving programs deemed to function primarily as inducements rather than genuine education. Speaker program income remains real and available, but companies are increasingly disciplined about program frequency, audience size, venue cost, and repeat engagement limits per physician — a physician entering this space in 2026 should expect a more tightly governed program than existed a decade ago.

3. Expert Network Consulting

This is the fastest-growing, most flexible, and most misunderstood category of pharma-and-biotech-adjacent physician income. Expert network platforms — the largest being GLG (Gerson Lehrman Group), Guidepoint, AlphaSights, and Third Bridge — connect physicians and other subject matter experts with clients who are overwhelmingly investment managers, hedge funds, private equity firms, and management consulting firms conducting due diligence on healthcare investments, not pharmaceutical companies marketing products directly. This is an important distinction: much of expert network consulting income comes from finance-sector clients trying to understand clinical practice patterns, competitive drug or device dynamics, or a specific disease state — not from a pharma company paying a physician to discuss its own product.

How the engagement model works: After registering with one or more networks (typically vetted based on your CV, board certifications, and area of expertise), you receive project invitations by email — a client wants to speak with a physician with your specific background about a defined topic. You review the topic, confirm no conflicts of interest exist (importantly, you cannot discuss confidential information about your own employer, ongoing unpublished research, or material non-public information), and complete a scheduled call, typically 30 to 60 minutes.

Compensation structure — the part physicians consistently underestimate: Expert network rates are genuinely set by the physician within a market range, and they are considerably higher than most physicians expect on first exposure to the platform. Early-career or generalist experts typically start in the $150 to $300 per hour range; mid-level professionals with strong, specific domain experience often set rates of $300 to $600 per hour; and senior physicians with highly specialized, in-demand expertise (particularly in oncology, rare disease, or emerging therapeutic categories with active investment interest) frequently command $600 to $1,200 or more per hour, with select highly sought-after specialists reportedly commanding several thousand dollars for a single hour of insight.

Payment is typically calculated by the minute rather than a flat hourly block — a 66-minute call at a $500/hour rate pays 110 percent of the stated hourly rate, while a call that runs only 30 minutes pays only half. Most networks pay out within roughly two weeks of call completion. Beyond calls, networks also offer shorter, lower-effort paid surveys — typically $40 to $80 for 10 to 20 minutes — which some physicians find to be a genuinely efficient way to generate incremental income between more substantial engagements, particularly given how frequently physician-targeted surveys are commissioned.

The practical negotiation point: you generally set your own rate when registering for a project, and different networks will shop the same client project across their competing physician rosters — meaning if you are consistently declined at a given rate through one network, a modest downward adjustment (or trying a competing network for the same type of project) often resolves it. Networks known for more aggressively negotiating rates down, such as GLG, may require a lower quoted rate than networks that compete less on price.

4. Clinical Trial Investigator and Sub-Investigator Work

Serving as a principal investigator (PI) or sub-investigator on an industry-sponsored clinical trial is both a meaningful income source and — separately — a professional development pathway that builds the CV credibility that makes advisory board and expert network invitations more frequent. Compensation is typically structured per-patient-enrolled or as a defined per-visit/per-procedure fee schedule negotiated in the clinical trial agreement between the physician's practice or institution and the sponsor, and can represent a meaningful revenue stream for practices with an active research infrastructure — separate from, and layered on top of, standard clinical income.

The specific regulatory framework that applies here — and does not apply to advisory boards or speaker programs: Under FDA regulation 21 CFR Part 54, clinical investigators involved in any study that may support a future FDA marketing application must disclose specific financial interests and arrangements to the trial sponsor, who in turn discloses them to the FDA. This includes any equity interest in the sponsor exceeding $50,000, and any payments from the sponsor — exclusive of the direct costs of conducting the study itself — exceeding $25,000 in aggregate value during the study period or for one year following its completion. The purpose is explicit: the FDA evaluates whether an investigator's financial relationship with a sponsor is significant enough to potentially bias the study's reported results, and if so, what the sponsor did — through study design, blinding, or independent endpoint assessment — to mitigate that risk. Unlike Sunshine Act data (covered below), 21 CFR Part 54 financial disclosures are not published in a public database — they remain within the FDA's confidential review process.

5. Medical Monitor and Data Safety Monitoring Board (DSMB) Roles

A step beyond standard trial participation: physicians with relevant subspecialty and often biostatistics-adjacent experience can serve as a medical monitor (reviewing adverse events and safety data on an ongoing basis during a trial) or as a member of an independent Data Safety Monitoring Board overseeing a trial's safety data on behalf of patients and the sponsor. These roles typically pay a retainer or per-meeting fee and require a more specific research and safety-oversight background than general advisory board work, but represent some of the more intellectually substantial and better-compensated part-time opportunities in this space for physicians with a strong trial or biostatistics background.

The Legal Framework: Why This Isn't Simply "Consulting Income"

This is the section every physician entering pharma or biotech consulting income needs to understand before accepting a first engagement — and it is structured differently from the Stark Law framework covered in our Medical Director and CMO Compensation guide, because the legal mechanics that govern pharma/device consulting are not identical to those governing hospital medical directorships.

The Anti-Kickback Statute Is the Primary Federal Concern

The Stark Law is specifically about physician self-referrals for designated health services billed to Medicare or Medicaid — hospital, imaging, lab, and similar entity relationships. Pharmaceutical and device company consulting relationships are instead governed primarily by the federal Anti-Kickback Statute (AKS), a criminal statute that prohibits knowingly and willfully offering, paying, soliciting, or receiving remuneration to induce referrals of any item or service reimbursable under a federal healthcare program — a category broad enough to include prescribing a drug or using a device that is paid for by Medicare or Medicaid.

The practical implication: a consulting fee, advisory board honorarium, or speaker fee paid to a physician who also prescribes the paying company's product is a financial relationship that regulators scrutinize under the same "one-purpose test" described in our medical director guide — if inducing favorable prescribing or product use is even one purpose of the payment, alongside legitimate purposes, the arrangement can violate the statute. This is precisely why every legitimate pharmaceutical or device company requires a written consulting agreement specifying deliverables, sets compensation at documented fair market value (benchmarked the same way medical director fees are benchmarked — against industry survey data, adjusted for specialty and seniority), and does not tie payment to the volume of a physician's prescriptions, referrals, or product usage.

What this means for you as the physician: legitimate engagements will always come with a written agreement specifying the actual work product expected — attending a defined meeting, providing written feedback, delivering a presentation — never simply "for being a physician who prescribes our drug." If a company ever offers payment without a written agreement, without a defined scope of work, or explicitly tied to your prescribing volume, that is not a gray area — it is a direct red flag that the arrangement fails basic AKS compliance.

The Physician Payments Sunshine Act: Your Name, Publicly Reported

Separate from the AKS's prohibition on improper inducement, the Physician Payments Sunshine Act — a provision of the Affordable Care Act, formally implemented as CMS's Open Payments program — requires pharmaceutical and device manufacturers to publicly report, by physician name, essentially every payment and "transfer of value" over a small annual threshold. This includes consulting fees, speaking honoraria, advisory board payments, travel and lodging reimbursement, meals, and research payments.

What this means practically: any advisory board fee, speaker honorarium, or consulting payment you accept from a pharmaceutical or device manufacturer will appear, with your name attached, in the CMS Open Payments public database — searchable by anyone, including your patients, your employer, and journalists. This is not optional or something you can decline — the reporting obligation falls on the company, not on you, and there is no mechanism to opt out of legitimate reporting. You should, however, register in the CMS Open Payments system yourself to review data reported under your name and dispute any inaccuracies, since errors in company-submitted data do occur and are correctable only through a defined CMS dispute process.

The reputational dimension worth planning for: because this data is fully public and increasingly used by patients, journalists, and academic researchers studying prescribing patterns, physicians building a meaningful consulting income stream should expect that relationship to be visible and should be prepared to discuss it candidly if a patient or colleague asks — this is precisely why the underlying compliance (legitimate written agreements, fair market value compensation, real deliverables) matters beyond the legal risk itself; it is also the honest answer you give if anyone asks why your name appears in the database.

A note on state law: several states — including Connecticut, Massachusetts, Minnesota, Nevada, Oregon, Vermont, and the District of Columbia — impose additional state-level marketing and gift disclosure requirements on top of the federal Sunshine Act framework, some of which are not fully preempted by the federal reporting requirement. If you practice in one of these states, confirm with your compliance-savvy contact at the sponsoring company (or your own healthcare attorney, for larger or more frequent engagements) whether additional state-specific disclosure or restriction applies.

Your Employer's Conflict of Interest Policy: The Compliance Layer Physicians Most Often Skip

This is the practical compliance step that has nothing to do with federal law and everything to do with whether you are permitted to accept this income at all under your current employment.

Most hospital systems and academic medical centers have explicit institutional conflict of interest policies that require physicians to disclose outside industry relationships — often above a specific dollar threshold — before accepting them, and some require formal pre-approval rather than after-the-fact disclosure. Academic institutions in particular often impose time commitment caps (a maximum number of outside-activity days per year) and may restrict engagements involving companies whose products the institution purchases or uses.

Your employment contract may independently restrict this. Physician employment agreements frequently include outside-activities clauses requiring notice or consent before accepting compensated consulting work, and in some cases requiring the employer to review and approve the specific engagement, particularly if it could be construed as competing with the employer's own interests or creating a conflict with your clinical duties. Before accepting your first advisory board invitation or expert network registration, review your current employment agreement's outside-activities and moonlighting provisions — see our Physician Contract Negotiation guide and Physician Contract Red Flags guide for the complete framework on evaluating these clauses. A physician who accepts undisclosed outside consulting income in violation of an explicit employer policy risks disciplinary action independent of whether the underlying pharma/device company relationship was itself perfectly compliant with federal law.

Expert network platforms specifically require you to confirm the absence of employer conflicts before every engagement — most reputable networks build a compliance screening step into each project invitation, asking you to confirm you are not disclosing confidential information about your employer, current unpublished research, or material non-public information about a publicly traded company. Take this screening seriously; it exists because expert networks themselves face significant regulatory and reputational risk if their consultants breach confidentiality or trade on inside information, and violating it can create personal legal exposure for you as well, particularly in engagements involving investment-firm clients evaluating publicly traded pharma or biotech companies.

The Tax Treatment: This Is 1099 Income

Virtually all of the income streams described above — advisory board fees, speaker honoraria, expert network consulting payments, and most clinical trial investigator fees paid directly to a physician rather than routed through an institution — are reported on Form 1099-NEC as self-employment income, not W-2 wages.

What this means practically:

• •You are responsible for both the employer and employee portions of Social Security and Medicare tax (self-employment tax) on this income, in addition to ordinary federal and state income tax.
• •You should be making quarterly estimated tax payments on this income if it reaches a meaningful annual total, since no employer is withholding tax on your behalf — a physician who earns $40,000 in a given year from advisory boards and expert network calls without adjusting withholding or making estimated payments can face an unpleasant surprise, and potentially an underpayment penalty, at tax filing time.
• •You may be eligible to establish a Solo 401(k) based on this self-employment income, opening up a meaningful additional tax-advantaged retirement savings opportunity layered on top of your primary employer's retirement plan — this is the same mechanism covered in depth in our Locum Tenens Tax guide, and it applies equally to consulting income from pharma and biotech engagements.
• •Legitimate business expenses are deductible against this income — home office space genuinely used for consulting preparation, a portion of your internet and phone expenses, travel directly related to an advisory board or speaker engagement not otherwise reimbursed, and professional development directly tied to maintaining the expertise that generates this income.

Given the mix of self-employment tax, quarterly estimated payment obligations, and retirement account opportunity this income creates, a physician generating more than a few thousand dollars annually from this category should have this specifically incorporated into their broader tax planning conversation — see our Physician Tax Planning guide and our Financial Advisors for Physicians review page for CPAs experienced with physician-specific 1099 income structures.

The Full-Time Exit: In-House Medical Director Roles at Pharma and Biotech Companies

For physicians whose actual goal is a complete transition out of clinical practice rather than supplemental income, the physician-appropriate version of pharma/biotech industry work is typically titled Medical Director (or Associate/Senior Medical Director, depending on seniority) within a company's medical affairs, clinical development, or pharmacovigilance function — a structurally different role from the field-based MSL position, based in a home office or corporate headquarters rather than constant field travel, and staffed predominantly by MD/DO physicians rather than PharmD/PhD professionals.

What these roles actually do: medical monitoring for ongoing clinical trials, safety signal review and pharmacovigilance oversight, medical review of promotional and scientific materials for regulatory compliance, clinical strategy input on drug development programs, and often direct interaction with the FDA during the regulatory review process.

The honest trade-off physicians considering this path should weigh: compensation for these roles is genuinely competitive — often exceeding many clinical specialties once base salary, bonus, and equity (particularly at earlier-stage biotech companies) are combined — but the transition typically means giving up direct patient care entirely, walking away from any accumulated PSLF-qualifying payment progress if applicable, and re-entering an unfamiliar corporate career track where advancement, culture, and job security operate on principles very different from clinical medicine. This is a career decision, not a side-income decision, and deserves the same deliberate evaluation as any other major practice-model change — see our Physician Burnout and Finances guide for the broader framework on evaluating whether a full transition away from clinical practice is the right move for your specific financial and personal situation.

How to Actually Get Started

• •Build the credibility that makes you findable. Advisory board and expert network invitations flow toward physicians with a visible professional profile: peer-reviewed publications, presentations at national specialty conferences, leadership roles in relevant professional societies, and meaningful clinical or procedural volume in a specific therapeutic area. There is no formal application process for most of this work — companies and market research firms actively search for and recruit physicians who already look like credible experts in a defined niche.
• •Register with one or two reputable expert networks if flexible, lower-commitment consulting income is your goal. This requires submitting your CV and credentials for vetting, after which project invitations arrive by email as clients request experts matching your specific background. Start with a defensible, moderate hourly rate reflecting your genuine seniority and specificity of expertise (see the rate tiers above), and adjust based on how frequently you are actually being booked at that rate.
• •Say yes to your first advisory board invitation even if the topic feels narrow. A single advisory board engagement, done well, is frequently how physicians enter a company's ongoing roster for future advisory work, speaker consideration, and trial investigator opportunities — the first engagement is disproportionately valuable for the relationship it opens, not just the honorarium it pays.
• •Confirm your employer's outside-activity policy before your first engagement, not after. This is the single most commonly skipped step, and the one most likely to create an avoidable problem — five minutes reviewing your employment contract's outside-activities clause, or a quick email to your institution's conflict of interest office, prevents a genuinely compliant pharma consulting engagement from becoming an unnecessary employment problem.

Frequently Asked Questions